| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Not defined; it is a drug derivative. The exact molecular target of WAY-311474 has not been identified. It is described as a bioactive molecule for research into amyloid diseases (e.g., Alzheimer's) and synucleinopathies (e.g., Parkinson's). Its mechanism of action likely involves preventing or clearing protein aggregates (amyloid-beta or alpha-synuclein), which are hallmarks of these conditions.
|
|---|---|
| ln Vitro |
No specific in vitro activity data has been reported. Given its intended use, it is predicted to interfere with the aggregation of pathological proteins like amyloid-beta (Abeta) or alpha-synuclein. This could be studied using Thioflavin T (ThT) fluorescence assays, where the compound would reduce the fluorescence signal of aggregated protein fibrils. It may also have anti-inflammatory or antioxidant activities.
|
| ln Vivo |
No specific in vivo activity data has been reported. As a potential therapeutic for neurodegenerative diseases, it would be studied in transgenic mouse models of Alzheimer's (e.g., APP/PS1 mice) or Parkinson's (e.g., A53T alpha-synuclein mice). Endpoints would typically include the reduction of amyloid plaque or Lewy body pathology, improvement in cognitive function (e.g., Morris water maze), and reduction of neuroinflammation.
|
| Enzyme Assay |
Not applicable, as the target has not been defined. To study its anti-aggregation properties, a typical protocol would involve incubating WAY-311474 (1-100 uM) with amyloid-beta (Abeta1-42) peptides (20 uM) in a 96-well plate in PBS (pH 7.4) containing 20 uM Thioflavin T. The plate is incubated at 37degC for 24-72 hours. Fluorescence (excitation 440 nm, emission 480 nm) is measured every hour to monitor the kinetics of fibril formation and the compound's ability to inhibit aggregation. A decrease in fluorescence indicates inhibition.
|
| Cell Assay |
For in vitro cellular studies, SH-SY5Y neuroblastoma cells are seeded in 96-well plates (1×10⁴ cells/well). To induce a Parkinson's-like phenotype, cells are treated with MPP+ (1-methyl-4-phenylpyridinium) or 6-OHDA (6-hydroxydopamine). WAY-311474 is added at concentrations ranging from 0.1-50 uM for 24-48 hours. Cell viability is assessed by MTT assay. Intracellular reactive oxygen species (ROS) levels are measured using the DCFH-DA fluorescent probe. For Alzheimer's studies, SH-SY5Y cells overexpressing APP or treated with Abeta oligomers can be used; neuroprotection is measured by LDH release or caspase-3 activity.
|
| Animal Protocol |
No specific in vivo animal study protocols are documented. For a compound like this, a typical protocol would involve using transgenic mice (e.g., 8-12 month old APP/PS1 mice for Alzheimer's or A53T mice for Parkinson's). WAY-311474 would be administered daily via intraperitoneal (i.p.) injection or oral gavage at doses of 10-50 mg/kg for 4-12 weeks. The primary endpoints would be cognitive testing (e.g., Morris water maze for learning and memory), immunohistochemistry for protein aggregates (Abeta or alpha-synuclein) and glial markers (Iba-1, GFAP), and measurement of neuroinflammatory cytokines (IL-6, TNF-alpha) by qPCR or ELISA in brain homogenates.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data has been reported. As a small molecule with a molecular weight of 316.22 g/mol, it is likely to be reasonably lipophilic (cLogP >2), suggesting the potential to cross the blood-brain barrier (BBB), which is critical for an anti-neurodegenerative disease drug. However, this requires experimental confirmation. Its ADME profile is unknown.
|
| Toxicity/Toxicokinetics |
No specific toxicity data has been reported. As a research chemical targeting neurodegenerative diseases, it is presumed to have a low-to-moderate toxicity profile in vitro. The compound is expected to be stable under recommended storage conditions (4degC, protect from light). Comprehensive toxicological evaluation for clinical use has not been performed.
|
| Additional Infomation |
WAY-311474 is also known as N-(cyclohexylmethyl)-2-(2,4-dichlorophenoxy)acetamide. The compound belongs to the class of drug derivatives. It is being studied to evaluate its potential for treating protein aggregation disorders. For research use only, not approved for clinical therapy. Molecular formula: C15H19Cl2NO2.
|
| Molecular Formula |
C15H19CL2NO2
|
|---|---|
| Molecular Weight |
316.222862482071
|
| Exact Mass |
315.08
|
| Elemental Analysis |
C, 56.97; H, 6.06; Cl, 22.42; N, 4.43; O, 10.12
|
| CAS # |
569313-77-5
|
| PubChem CID |
2500767
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC(CC1)CNC(=O)COC2=C(C=C(C=C2)Cl)Cl
|
| InChi Key |
ORLRIVVUGJSCCY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H19Cl2NO2/c16-12-6-7-14(13(17)8-12)20-10-15(19)18-9-11-4-2-1-3-5-11/h6-8,11H,1-5,9-10H2,(H,18,19)
|
| Chemical Name |
(N-(cyclohexylmethyl)-2-(2,4-dichlorophenoxy)acetamide)
|
| Synonyms |
WAY-311474; WAY311474; WAY 311474
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1624 mL | 15.8118 mL | 31.6236 mL | |
| 5 mM | 0.6325 mL | 3.1624 mL | 6.3247 mL | |
| 10 mM | 0.3162 mL | 1.5812 mL | 3.1624 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
